Glenmark Pharmaceuticals Quarterly Results
Glenmark Pharmaceuticals quarterly results. In Sept 2026, Glenmark Pharmaceuticals (GLENMARK) reported revenue ₹4,160 Cr and net profit ₹264 Cr — revenue -32.9% YoY. Also explore GLENMARK share price history to track price trends across different timeframes.
GLENMARK Quarterly Results — Revenue, Profit & EPS Highlights
Glenmark Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View GLENMARK 52-week performance for the annual high/low range and current price position.
- Revenue of ₹4,160 Cr in Sept 2026 (+5.3% vs Mar 2026, -32.9% vs Sept 2025)
- Net Profit of ₹264 Cr in Sept 2026 (-12.3% vs Mar 2026, -56.7% vs Sept 2025)
- EBITDA of ₹492 Cr in Sept 2026 (-13.4% vs Mar 2026)
- Operating Margin of 12.0% in Sept 2026 (+2.0pp vs Mar 2026)
- Earnings Per Share of ₹9.35 in Sept 2026 (-12.5% vs Mar 2026)
Glenmark Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GLENMARK quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 4,160 | 3,949 | 3,998 | 6,204 | 3,232 | 5.3% | -32.9% |
| Net Profit (₹ Cr) | 264 | 301 | 483 | 610 | 4 | - | - |
| EBITDA (₹ Cr) | 492 | 568 | 784 | 1,132 | 164 | - | - |
| EPS (₹) | 9.35 | 10.68 | 17.11 | 21.63 | 0.16 | - | - |
| Operating Margin (%) | 12.0% | 10.0% | 18.0% | 16.0% | 5.0% | - | - |
GLENMARK Share Price Trend — 1-Year Movement Across Quarterly Results
Glenmark Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Glenmark Pharmaceuticals screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GLENMARK vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Glenmark Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores